Form D · Biotechnology
Longeveron Inc.
Miami, FL · CIK 0001721484
Offering snapshot reported Mar 25, 2026 · SEC filing
- Reported sold
- $15.9M Offering amount: $33.5M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 11, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 25, 2026 | Initial | $15,890,000 | No comparison | 7 | SEC filing |
| Jul 23, 2024 | Initial | $0 | No comparison | 3 | SEC filing |
| Jun 25, 2024 | Initial | $0 | No comparison | 3 | SEC filing |
| Apr 25, 2024 | Initial | $0 | No comparison | 3 | SEC filing |
| Jan 8, 2024 | Initial | $0 | No comparison | 1 | SEC filing |
| Oct 24, 2023 | Initial | $0 | No comparison | 1 | SEC filing |
| Dec 13, 2021 | Initial | $20,462,545 | No comparison | 20 | SEC filing |
| Feb 6, 2020 | Amendment | $954,970 | $430,000vs Apr 5, 2018 | 5 | SEC filing |
| Feb 6, 2020 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Apr 5, 2018 | Amendment | $524,970 | $225,000vs Nov 6, 2017 | 2 | SEC filing |
| Nov 6, 2017 | Initial | $299,970 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.22M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-577617
Total offering amount: purchase price of shares of Class A common stock, Series A Preferred Stock, an interest in future proceeds from a potential future PRV sale, proceeds due to Company assuming cash exercise of all warrants issued to placement agent
An interest in 50% of proceeds received (after deducting fees) from the potential future sale of a Rare Pediatric Disease Priority Review Voucher, to the extent received from the U.S. FDA in connection with the Company's laromestrocel program for HLHS.
At initial closing, placement agent received $1,112,300.01 & warrants to purchase up to 2,019,231 shares of Common Stock exercisable at $0.65 per share, among other items. Contingent upon a second closing, placement agent will receive an identical comp.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 | Michael Vasinkevich · CRD 2843810 |
Source: Form D, filed Mar 25, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nataliya Agafonova | Executive |
| Khoso Baluch | Director |
| Devin Blass | Executive |
| Erin Borger | Director |
| James Clavijo | Executive |
| Geoff Green | Executive |
| Roger Joseph Hajjar | Director |
| Neil E. Hare | Director |
| Joshua M. Hare | Director, Executive |
| Wa'el Hashad | Director, Executive |
| Richard Kender | Director |
| Paul Lehr | Executive |
| Lisa A. Locklear | Executive |
| Douglas Losordo | Director |
| Neha J. Motwani | Director |
| Suzanne Page | Executive |
| George Paletta, Jr. | Director |
| Jeffrey Pfeffer | Director |
| Cathy Ross | Director |
| Rock Soffer | Director |
| Donald Soffer | Director |
| Ursula Ungaro | Director |
| Stephen H. Willard | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1951 Nw 7 Th Avenue Suite 520
Miami, FL, 33136
Miami, FL, 33136